Dyax Corp. (NASDAQ:DYAX) announced that its Hereditary Angioedema Drug has met the primary endpoint. The company at present, is working on its drug called DX-2930 in the multiple-ascending dose phase Ib, placebo-controlled, double-blind, randomized, multi-center study. DX-2930 will be used for preventing HAE or hereditary angioedema attacks.
All primary objectives met during study
According to the company, Pharmacokinetic results have proven that the drug offered dose-dependent and linear exposure with the half-line mean elimination of approximately 14 days from the dose groups of all kinds, viz. 400 mg, 300 mg, 100 mg and 30 mg. The company also announced that their drug DX-2930 was well accepted by all the patients.
It was also observed that there was reduced reduction in the attack rate among patients who took DX-2930, in comparison to the ones taking placebo.
Fast track designation assigned to DX-2930
Apart from announcing the results of the study, the company also announced about the enhanced designation of DX-2930. The drug was given fast track position for DX-2930 by the Food and Drug Administration. FDA now gave it the HAE position. The company said that it now intended to convey about these results to Administration, while also leveraging the advantages from the fast track status of DX-2930. This status will enable the company in finding ways for fast approval as well.
HAE and its impact on people
Hereditary angioedema attacks or HAE has an impact over approximately 1 out of 10,000 people or 1 out of 50,000 people across the world. Shire PLC (ADR) (NASDAQ:SHPG)’s drugs, Cinryze and Firazyr have already been approved for treating the HAE drugs. Dyax Corp.’s drug DX-2930 will only add to the betterment of people and an increased competition among the aforementioned treatments for HAE. After its final signal of approval from the U.S. FDA, DX-2930 might start selling commercially in the markets.